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Abstract
Background: Gemcitabine/Cisplatin (Gem/CDDP) combination has demonstrated a clear survival advantage over
gemcitabine alone and has become a new standard in advanced Biliary Tract Carcinoma (aBTC). However,
Gemcitabine/Oxaliplatin (GEMOX) combination and Gemcitabine/Carboplatin (Gem/Carb) combination regimens
have shown efficacy in phase II trials and there is no comparative study between different platinum salts.
We assessed the efficacy and safety of different platinum-based chemotherapies at first line in aBTC patients. We
also analysed the second-line chemotherapy.
Methods: Sixty-four consecutive patients with aBTC diagnosed between 1998 and 2010 were included for analysis.
At first line chemotherapy, 44 patients received one day GEMOX regimen (gemcitabine 1000 mg/m2 and oxaliplatin
100 mg/m2 Day 1, every 2 weeks), and 20 patients received Gem/Carb regimen (gemcitabine at 1000 mg/m2 Days
1 and 8 with carboplatin delivered according to an area-under-the-curve (AUC) 5 at day 1, every 3 weeks). At
second line, a total of 16 patients received a fluoropyrimidine-based chemotherapy.
Results: With GEMOX regimen, median progression-free survival (PFS) was 3.7 months (95%CI, 2.4 to 5) and median
overall survival (OS) was 10.5 months (95%CI, 6.4 to14.7). The main toxicity was peripheral neuropathy (20% grade 2
and 7% grade 3). Grade 3/4 haematological toxicities were rare.
With Gem/Carb regimen, PFS was 2.5 months (95%CI, 2.1 to 3.7) and OS was 4.8 months (95%CI, 3.7 to 5.8). The
main grade 3/4 toxicities were haematological: anaemia (45%), thrombocytopenia (45%), and neutropenia (40%).
At second-line, fluoropyrimidine-based chemotherapy was feasible in only a fourth of the patients. The median OS
was 5.3 months (95%CI, 4.1 to 6.6), and median PFS was 4.0 months (95%CI, 2.6 to 5.5).
Conclusions: One day GEMOX regimen has a favourable toxicity profile and could be an alternative to standard
Gem/CDDP regimen, in particular in unfit patients for CDDP.
At second-line, selective patients may benefit from fluoropyrimidine-based chemotherapy.
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Background
Biliary tract carcinomas (BTCs) are invasive adenocar-
cinomas that arise from the epithelial cells of the biliary
tree, which comprises intrahepatic and extrahepatic bile
ducts, and gallbladder. Even though BTCs are consid-
ered as rare tumours, they represent about 30% of the
total primary liver cancers with an incidence rate close
to that of hepatocarcinoma. Approximately 1200 new
cases in the United Kingdom and 9000 in the United
States are diagnosed per year. Unfortunately, only a mi-
nority of patients diagnosed with these aggressive tu-
mours are at an early resectable stage, and disease
recurrence rates are high despite curative-intent surgery.
Prognosis of patients with advanced BTC is extremely
poor with OS less than 1 year [1,2].
Chemotherapy represents a palliative treatment option
for patients with advanced disease with significant bene-
fit in OS and quality of life (QoL) over best supportive
care (BSC) alone [3].
Different single or combination-drug regimens have
demonstrated some activity in BTCs, including fluoro-
pyrimidines, gemcitabine, and platinum salts [3-7]. A
pooled analysis from Eckel et al. included 104 trials
comprising 2810 patients. Even though only 3 small
randomized trials were included in this study, they
suggested gemcitabine combined with cisplatin or oxa-
liplatin as the most active, and therefore they were
considered as the provisional standard regimens in
aBTC [8].
Different GEMOX regimens were assessed in several
phase II clinical trials with OS no longer than 12 months
[9-12]. In 2010, a randomized multicenter phase III
ABC-02 trial established Gem/CDDP as a standard regi-
men in aBTC. OS was 11.7 months in favour to combin-
ation arm compared to 8.1 months in gemcitabine arm
(HR, 0.64; 95%CI 95%, 0.52 to 0.80; P < 0.001) [13]. Be-
fore ABC-02 trial results, our multidisciplinary com-
mittee approved Gem/Carb combination as standard
regimen in aBTC up to December 2003, and biweekly
GEMOX regimen thereafter, based in existing data at
that time.
In second-line, in our knowledge, no trial assessed the
benefit of chemotherapy over BSC in aBTCs. Even
though there is no clear evidence-based data for a stand-
ard regimen in second line, fluoropyrimidine-based che-
motherapies are largely applied.
The aim of this retrospective study was to evaluate the
OS, PFS, and safety in patients with aBTCs treated in
first line chemotherapy by modified one day GEMOX or
Gem/Carb regimen in our institution comprising three
different hospitals.
We also analysed the efficacy in terms of survival of
second line chemotherapy based on fluoropyrimidines.
Methods
Study population
Between 1998 and 2010, 64 consecutive patients were
retrospectively included in two general hospitals and one
university hospital belonging to IRFC-FC (Institut
Régional Fédératif du Cancer de Franche-Comté).
Patients were eligible if they had histologically docu-
mented BTC including intrahepatic BTC, extrahepatic
BTC and gallbladder cancer, unresectable or metastatic
disease, and received at least one cycle of chemotherapy.
Treatment
At first line, patients with aBTC received Gem/Carb regi-
men until December 2003. From January 2004 to 2010, all
patients received GEMOX regimen. Twenty patients re-
ceived Gem/Carb regimen (gemcitabine at 1000 mg/m2
on days 1 and 8, with carboplatin dosed at an AUC of 5
on day 1 of a 21-day cycle), and 44 patients received
GEMOX regimen (gemcitabine 1000 mg/m2 on day 1,
with oxaliplatin 100 mg/m2 on day 1, every 2 weeks).
At second line, 16 of 64 patients reviewed (25%) re-
ceived chemotherapy; all regimens were based on 5FU/
leucovorin (LV5FU2) or capecitabine. Eleven patients re-
ceived a mono-chemotherapy (either LV5FU2 or capecita-
bine) and 5 patients a bi-chemotherapy (either FOLFOX
or FOLFIRI).
Statistical analysis
The primary end point was the treatment efficacy of first
line chemotherapy in terms of OS. Secondary endpoints
were PFS and toxicity of the GEMOX and Gem/Carb
regimens as first-line therapy, treatment efficacy of
second-line chemotherapy in terms of OS and PFS. OS
was defined as the time from the first chemotherapy to
death from all causes. PFS was defined as the time from
the first chemotherapy to the earliest date of disease
progression (local, regional, distant and second cancer),
death (from all causes) or data cut-off (from all causes).
OS and PFS were estimated using Kaplan Meier method
and described by median with 95% Confidence Interval
(CI). Survival curves were compared using log-rank test.
Safety was reported for all subjects who received at
least one dose of chemotherapy.
The ethical committee, Comité de protection des per-
sonnes Est-II, approved the protocol.
Results
Patients
Patient’s baseline characteristics are presented in Table 1.
The population included 38 males and 26 females (ratio,
1.46), with a mean age of 65 years (range, 34–84).
Twenty-nine patients presented intrahepatic BTC, 15
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patients presented extrahepatic BTC, and 20 patients
had gallbladder cancer. No ampulloma was included in
our cohort. Twenty-nine patients were treated with prior
tumour resection, and 9 patients received prior radio-
therapy. Most patients (74%) were in good performance
status at diagnosis (Eastern Cooperative Oncology
Group – Performance Status, ECOG-PS 0–1) (Table 1).
Efficacy
Twenty patients received Gem/Carb regimen. Mean age
was 62 years (range 34–78) with 9 males and 11 females
(ratio, 0.82). Fourteen patients (70%) presented ECOG-PS
of 0–1 at diagnosis. All 20 patients were dead at the time
of analysis. (Table 1) There were 1 CR (5%), 1 PR (5%), 6
SD (30%) and 12 (60%) progression disease (PD). Median
OS was 4.8 months (95%CI, 3.7 to 5.8) (Figure 1), and me-
dian PFS was 2.5 months (95%CI, 2.1 to 3.7) (Figure 2).
One patient who had primarily unresectable disease under-
went curative-intent surgery after chemotherapy. Recur-
rence free survival (RFS) in this patient was 11.9 months.
Forty-four patients received GEMOX regimen. Mean
age was 66 years, (range 47–84 years) with 29 males and
15 females (ratio, 1.93). Thirty-four patients (77%)
presented ECOG-PS of 0–1 at diagnosis. Eleven patients
were alive at the time of analysis with a median follow-
up of 35 months. (Table 1) There were 3 CR (7%), 5 PR
(11%), 9 SD (20%) and 27 PD (61%). Median OS was
10.5 months (95%CI, 6.4 to 14.7) (Figure 1), and median
PFS was 3.7 months (95%CI, 2.4 to 5) (Figure 2). In 2
patients the tumour became resectable after chemother-
apy. Their RFS was 13.3 and 14.3 months.
Among 64 patients treated with platinum/gemcitabine
combinations as front-line regimen, 8 patients (13%) had
a median OS > 24 months.
Safety
Chemotherapy was administered until progression, un-
acceptable toxicity, or curative-intent surgery. Two pa-
tients in GEMOX cohort stopped the chemotherapy
after 37th cycle due to a long lasting complete response
of metastases. The median relative dose intensities in
GEMOX cohort were 96% and 93% for gemcitabine and
oxaliplatine, respectively; and in the Gem/Carb cohort
were 97% and 95% for gemcitabine and carboplatin, re-
spectively. The main reason for treatment discontinu-
ation was disease progression. Only 3 patients (7%) in
GEMOX cohort and one patient (5%) in Gem/Carb co-
hort stopped the treatment for toxicity. The median
number of treatment cycles administered was 7 (range,
1–37) in the GEMOX cohort and 3 (range, 1–7) in the
Gem/Carb cohort. More patients in the GEMOX cohort
received 16 or more weeks of treatment (49% v 29%).
In GEMOX regimen, the main toxicity was the periph-
eral neuropathy, present in 59% of patients including 7%
with grade 3 neuropathy. Anaemia was observed in 43%
(2% grade 3, no grade 4), and thrombocytopenia was ob-
served in 36% (2% grade 3, no grade 4).
Concerning Gem/Carb regimen, the main toxicity was
haematological. Anaemia was observed in 75% of pa-
tients (40% grade 3, 5% grade 4), thrombocytopenia in
60% (30% grade 3, 15% grade 4), and neutropenia in 50%
(30% grade 3, 10% grade 4) (Table 2).
Second line chemotherapy
Sixteen patients received second line chemotherapy.
Median OS was 5.3 months (95%CI, 4.1 to 6.6), and me-
dian PFS was 4.0 months (95%CI, 2.6 to 5.5). Median
OS was 5.2 months (95%CI, 3.8 to 6.6) for the mono-
chemotherapy group as compared to 6.1 months (95%
CI, 2.0 to 10.3) in the bi-chemotherapy group. Median
PFS was 3.8 months (95%CI, 2.7 to 4.9) for the mono-
chemotherapy group as compared to 4.4 months (95%
CI, 2.9 to 6.0) in the bi-chemotherapy group. No signifi-
cant difference was found between the two groups (p =
0.98 and p = 0.68, respectively).
Table 1 Patient and tumour characteristics
Characteristics n (%) GEMOX (n = 44) Gem/Carb (n = 20) p
n (%) n (%)
Year of diagnosis 2004-2010 1998-2003
Gender, no (%)
Male 29 (66) 9 (45) 0.17
Female 15 (34) 11 (55)
Age
<=67 19 (43) 12 (60) 0.28
>67 25 (57) 8 (40)
ECOG PS, no. (%)
0-1 34 (77) 14 (70) 0,75
2-3 10 (23) 6 (30)
Primary tumour location
Gallbladder 12 (27) 8 (40) 0.59
Intrahepatic bile ducts 21 (48) 8 (40)
Extrahepatic bile ducts 11 (25) 4 (20)
Ampulla of Vater 0 (0) 0 (0)
Prior treatment for BTC
Surgery 22 (50) 7 (37) 0.40
Radiotherapy 5 (11) 4 (21)
Number of metastatic sites
1 26 (59) 11 (58) 0.81
>1 18 (41) 8 (42)
Abbreviations: GEMOX gemcitabine and oxaliplatine combination regimen,
Gem/Carb gemcitabine and carboplatin combination regimen, ECOG-PS Eastern
Cooperative Oncology Group  Performance Status, BTC biliary tract carcinomas.
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Figure 1 Overall survival. GEMOX regimen (n = 44) and Gem/Carb regimen (n = 20).
Figure 2 Progression free survival. GEMOX regimen (n = 44) and Gem/Carb regimen (n = 20).
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Discussion
A phase III ABC-02 trial including 410 patients demon-
strated overall survival superiority of Gem/CDDP com-
bination over gemcitabine alone, establishing a new
standard in front-line chemotherapy for aBTCs (11.7 vs.
8.2 months, HR 0.64; 95%CI, 0.52 to 0.80; P < 0.001).
The PFS was 8.0 months in the Gem/CDDP arm versus
5.0 months in the control arm (P < 0.001). Adverse
events were similar in both groups, with the exception
of more neutropenia in the combination arm [13].
Oxaliplatin is active as monotherapy in patients with
BTC [7]. Synergic antitumoral effect with gemcitabine
was seen in preclinical studies [14]. Several phase II
trials support the use of oxaliplatin combined to gemci-
tabine in aBTC [9-12]. André et al. conducted a multi-
national phase II trial and 70 patients were treated by
GEMOX regimen (gemcitabine 1000 mg/m2 Day 1, and
oxaliplatin 100 mg/m2 Day 2, every two weeks). Median
OS rate was 8.8 months (95%CI, 6.9 to 11.1) and toler-
ance profile was favourable. Sharma et al. evaluated
efficacy of modified gemcitabine and oxaliplatin (mGE-
MOX) over BSC or fluorouracil and folinic acid (FUFA)
(gemcitabine 900 mg/m2 and oxaliplatin 80 mg/m2,
both Day 1, and 8, every 3 weeks). Median OS was 9.5,
4.5, and 4.6, months for mGEMOX, BSC, and FUFA (P =
0.039), respectively [15]. A pooled analysis of 104 trials
with 2810 patients suggests that gemcitabine and plat-
inum combination, including oxaliplatin may improve sur-
vival compared to other regimens [8]. Superiority of one
platinum salt over another in this setting was not demon-
strated, and there is no clinical trial with direct compari-
son between different platinum salts in BTCs, nether
between different GEMOX regimens.
In our study, we used biweekly GEMOX regimen.
However it is slightly different to André’s one. Both,
gemcitabine and oxaliplatin are administered at day 1
with gemcitabine preceding oxaliplatin. Our result,
based in non-selected patients, showed an OS of
10.5 months. Even though our cohort has several limita-
tions like a small number of patients, retrospective ana-
lysis, and no control arm, this OS result is still
encouraging since there were more ECOG-PS 2 patients
and a higher median age than in randomized or well de-
signed phase II trials. The treatment was well tolerated.
The main toxicity was peripheral neuropathy observed
in 59%. Oxaliplatin was stopped in 3 patients for grade 3
peripheral neuropathy. Other grade 3 toxicities were rare
and no grade 4 was reported. In ABC-02 study, more
than 70% of patients presented grade 3/4 toxicities in
Gem/CDDP arm, and significantly more haematological
toxicities were observed compared to gemcitabine alone.
Gem/Carb combination was successfully assessed in
several phase III trials for tumours from different sites
(e.g., lung, and bladder cancers) [16-18]. In aBTCs, Wil-
liams and al conducted a phase II trial (gemcitabine
1000 mg/m2 and 8 and carboplatin AUC 5 Day 1, every
three weeks) and 48 patients were consecutively in-
cluded with a median OS of 10.6 months (95%CI, 8.8
to14.2) [19]. Our cohort did worse with the same treat-
ment schedule. Even though 20 patients are certainly
underpowered to estimate OS, it was only 4.8 months
(95%CI, 3.7 to 5.8). Grade 3/4 toxicities were frequent,
including grade 4 haematological toxicities.
Health related QoL is a major concern in this palliative
setting. Number of visits is in favour of our GEMOX
regimen with 2 visits per month compared to 3 in the
Table 2 Adverse events
Adverse events. No. (%) All grades (1–4) Grade 3 Grade 4
GEMOX Gem/Carb GEMOX Gem/Carb GEMOX Gem/Carb
(n = 44) (n = 20) (n = 44) (n = 20) (n = 44) (n = 20)
Haematological
Anaemia 19 (43) 15 (75) 1 (2) 8 (40) 0 1 (5)
Thrombocytopenia 16 (36) 12 (60) 1 (2) 6 (30) 0 3 (15)
Neutropenia 4 (9) 10 (50) 0 6 (30) 1 (2) 2 (10)
Febrile neutropenia 1 (2) 0 0 0 0 0
Non haematological
Fatigue 14 (32) 4 (20) 0 2 (10) 0 0
Nausea 10 (23) 3 (15) 0 2 (10) 0 0
Vomiting 6 (14) 4 (20) 0 3 (15) 0 0
Liver toxicity 3 (7) 2 (10) 0 0 0 0
Peripheral neuropathy 26 (59) 0 3 (7) 0 0 0
Infection without neutropenia 9 (21) 1 (5) 0 1 (5) 0 0
Renal toxicity 2 (5) 0 0 0 0 0
Abbreviations: GEMOX gemcitabine and oxaliplatine combination regimen, Gem/Carb gemcitabine and carboplatin combination regimen.
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same period for Gem/CDDP and Gem/Carb regimens,
and 4 visits for classic GEMOX regimens. However, the
benefit of a limited number of visits in terms of QoL
was not demonstrated. Moreover, compared to standard
Gem/CDDP, GEMOX regimen needs no hyperhydration
and has probably minor risks of renal complication.
GEMOX regimen is already considered as a standard
arm in new studies like BINGO trial, which compares
GEMOX plus cetuximab versus GEMOX alone [20].
In second line, there are limited clinical data to suggest
a clinical benefit of chemotherapy in aBTC and there is no
regimen considered as standard in this setting. However,
anticancer activity of fluoropyrimidines in BTC is well
known [6]. Recently, a phase II trial evaluated capecitabine
and oxaliplatin combination as second-line regimen in
pancreatic cancers and BTCs. All patients progressed after
gemcitabine-based regimen. Forty patients were assessed
including 17 BTCs. DCR was 22%, PFS was 15 weeks
(95%CI, 6.6 to 23.3), and OS was 19 weeks (95%CI, 10.4 to
27.5) [21]. These results are similar to that observed in
our cohort with a PFS of 4 months (95%CI, 2.6 to 5.5) and
OS of 5.3 months (95%CI, 4.1 to 6.6). Even though only a
fourth of patients was able to receive second-line chemo-
therapy, fluoropyrimidine-based chemotherapy may add
clinical benefit in this selected population since median
survival rates were not negligible. However, the clinical
interest on the administration of a more toxic bichem-
otherapy over monochemotherapy in this palliative setting
needs to be demonstrated.
Conclusion
In conclusion, one day GEMOX regimen has a favourable
toxicity profile and could be an alternative to standard Gem/
CDDP regimen, in particular in unfit patients for CDDP.
At second-line, selective patients may benefit from
fluoropyrimidine-based chemotherapy.
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